Evidence map›Paper›PMID 42016606›Full record

ArticleACG case reports journal2026

Liver Transplantation After Prolonged Nab-Sirolimus Therapy for Unresectable Hepatic Perivascular Epithelioid Cell Tumor With Bilobar Involvement.

Andrew John Cruz, Dylan Russell, Phillip M Cheng, Mark Agulnik, Shefali Chopra, Mark Sturdevant, Navpreet Kaur, Jeffrey A Kahn

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrew John CruzDepartment of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA.ORCID https://orcid.org/0009-0006-2035-3024
Dylan RussellDepartment of Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA.
Phillip M ChengDepartment of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA.
Mark AgulnikDepartment of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA.
Shefali ChopraDepartment of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA.
Mark SturdevantDepartment of Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA.
Navpreet KaurDepartment of Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA.
Jeffrey A KahnDepartment of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary hepatic perivascular epithelioid cell tumor (PEComa) is rare, and management of unresectable disease is not established. A 47-year-old woman had an 8-cm central hepatic PEComa bridging both lobes with tuberous sclerosis complex 2 alterations. She received albumin-bound sirolimus for 26 months with modest size reduction but durable stability, enabling listing with a nonstandard model for end-stage liver disease exception. She underwent right trisegment orthotopic liver transplantation, and the explant showed a well-circumscribed PEComa without vascular invasion or additional lesions. This case highlights prolonged nab-sirolimus as a bridge to transplantation in selected patients with favorable tumor biology.

Indexed as

hepatic PEComaliver transplantationMELD exceptionmTOR inhibitornab-sirolimus

Identifiers

PMID42016606
PMCPMC13095264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.